Compare DOUG & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOUG | CRBU |
|---|---|---|
| Founded | 1911 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.4M | 138.3M |
| IPO Year | 2021 | 2021 |
| Metric | DOUG | CRBU |
|---|---|---|
| Price | $1.57 | $0.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | 555.6K | ★ 3.8M |
| Earning Date | 11-17-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.68 | 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $955,578,000.00 | N/A |
| Revenue This Year | $0.59 | $114.75 |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.38 | $0.41 |
| 52 Week High | $3.03 | $2.49 |
| Indicator | DOUG | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 49.85 | 27.27 |
| Support Level | $1.55 | N/A |
| Resistance Level | $1.65 | $0.58 |
| Average True Range (ATR) | 0.09 | 0.04 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 52.78 | 13.25 |
Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.